Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets

about

Trial watch: IDO inhibitors in cancer therapy Trial Watch: Peptide-based anticancer vaccines.FOXL2 molecular status in adult granulosa cell tumors of the ovary: A study of primary and metastatic cases

P2860

Q27006866-2A589382-81BD-4DCF-837C-E25A4F356665 Q34483345-5ADDCEB5-25DD-492D-957A-89D2D679DC4B Q37106535-D1800B8E-4C67-43BF-AFEF-3F2CA0751019

P2860

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets

Item

http://www.wikidata.org/entity/Q41845397

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Biological insights into BRAF( ...... : Not mere therapeutic targets

@en

type

Item

label

Biological insights into BRAF( ...... : Not mere therapeutic targets

@en

prefLabel

Biological insights into BRAF( ...... : Not mere therapeutic targets

@en

P1476

Biological insights into BRAF( ...... : Not mere therapeutic targets

@en

P2093

Giuseppe Pelosi

http://www.w3.org/2001/XMLSchema#string

Giuseppina Improta

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Mutations of the BRAF gene in human cancer

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells

Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion.

Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.

Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.

IFN-alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome.

Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination.

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?

P304

e25594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.25594

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258216391

http://www.w3.org/2001/XMLSchema#string

P698

24179707

http://www.w3.org/2001/XMLSchema#string

P932

3812198

http://www.w3.org/2001/XMLSchema#string

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets

about

P2860

P2860

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932